Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: 597599; GW 597599; GW 597599B

Latest Information Update: 31 Aug 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Class Antidepressants; Antiemetics; Anxiolytics; Mesylates; Piperazines; Small molecules
  • Mechanism of Action Neurokinin 1 antagonists; Neurokinin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Anxiety disorders; Dyspepsia; Hearing loss; Major depressive disorder; Postoperative nausea and vomiting; Tinnitus

Most Recent Events

  • 29 Feb 2012 Phase-II clinical trials in Postoperative nausea and vomiting in USA (IV)
  • 21 May 2007 No development reported - Phase-II for Postoperative nausea and vomiting in USA (unspecified route)
  • 25 Nov 2005 Data presented at the 18th Annual Congress of the European College of Neuropsychopharmacology (ECNP-2005) have been added to the adverse events , pharmacokinetics and Anxiety disorders pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top